Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio, Inc. (NASDAQ: BLTE) announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. The company, a clinical-stage drug developer focused on retinal diseases, achieved this milestone by meeting the higher financial and liquidity standards required. The uplisting is expected to enhance visibility among institutional investors, improve liquidity, and broaden market recognition as the company continues advancing tinlarebant, its lead candidate for Stargardt disease treatment.